{"product_id":"recombinant-human-tnfa-protein-avi-his-tag","title":"Recombinant Human TNFa protein (Avi, His tag)","description":"\u003cp\u003e\u003cb\u003eSize\u003c\/b\u003e:100μg\u003c\/p\u003e\u003cp\u003e\u003cb\u003eStorage\u003c\/b\u003e:Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at \u0026lt; -20℃ for 3 months.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eShipping\u003c\/b\u003e:This product is provided as lyophilized powder which is shipped with ice packs.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExp date\u003c\/b\u003e:12 months\u003c\/p\u003e\u003cp\u003e\u003cb\u003eCategory ID_II\u003c\/b\u003e:Recombinant Proteins\u003c\/p\u003e\u003cp\u003e\u003cb\u003eCategory ID_III\u003c\/b\u003e:Others\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAbbreviation\u003c\/b\u003e:TNFa\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Synonym\u003c\/b\u003e:Cachectin;TNF;TNF-Alpha;TNF-a;TNFA;TNFSF2;Tumor Necrosis Factor\u003c\/p\u003e\u003cp\u003e\u003cb\u003eResearch Areas\u003c\/b\u003e:Signal Transduction;Cardiovascular;Cancer;immunology;metabolism\u003c\/p\u003e\u003cp\u003e\u003cb\u003eConjugation\u003c\/b\u003e:Biotinylated\u003c\/p\u003e\u003cp\u003e\u003cb\u003eTarget Species\u003c\/b\u003e:Human\u003c\/p\u003e\u003cp\u003e\u003cb\u003eExpression Host\u003c\/b\u003e:E.coli\u003c\/p\u003e\u003cp\u003e\u003cb\u003eApplication\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eFusion tag\u003c\/b\u003e:C-Avi-His\u003c\/p\u003e\u003cp\u003e\u003cb\u003eUNIProt ID\u003c\/b\u003e:P01375\u003c\/p\u003e\u003cp\u003e\u003cb\u003eAccession\u003c\/b\u003e:P01375\u003c\/p\u003e\u003cp\u003e\u003cb\u003eBackground\u003c\/b\u003e:Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF receptors. Based on these results, many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eConcentration\u003c\/b\u003e:\u003c\/p\u003e\u003cp\u003e\u003cb\u003eActivity\u003c\/b\u003e:Not validated for activity\u003c\/p\u003e\u003cp\u003e\u003cb\u003eSequence\u003c\/b\u003e:Gly 144-Leu 233\u003c\/p\u003e\u003cp\u003e\u003cb\u003ePurity\u003c\/b\u003e: \u0026gt; 95% as determined by reducing SDS-PAGE.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eFormulation\u003c\/b\u003e:Lyophilized from sterile PBS, pH 7.4.\u003cbr\u003eNormally 5%-8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization.\u003cbr\u003ePlease refer to the specific buffer information in the printed manual.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eReconstitution\u003c\/b\u003e:It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg\/mL. Concentration is measured by UV-Vis.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eEndotoxin\u003c\/b\u003e:\u0026lt; 10 EU\/mg of the protein as determined by the LAL method.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eCalculated MW\u003c\/b\u003e:9.8 kDa\u003c\/p\u003e\u003cp\u003e\u003cb\u003eObservedMW\u003c\/b\u003e:12 kDa\u003c\/p\u003e","brand":"GeneBio Systems","offers":[{"title":"Default Title","offer_id":48644112744548,"sku":"PDEH100866","price":413.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0558\/8588\/9636\/files\/no_image_default_image-jpeg_3102e439-3be9-4aa1-94ef-f6bd71f8a943.jpg?v=1782613200","url":"https:\/\/www.genebiosystems.com\/en-us\/products\/recombinant-human-tnfa-protein-avi-his-tag","provider":"GeneBio ","version":"1.0","type":"link"}